Physician profile
William Pena
NPI 1568427078
$4,142.70
in general payments reported to CMS, 2019-2025
36 companies · $626 in 2025
The $626 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $376 · 2021: $522 · 2022: $302 · 2023: $414 · 2024: $580 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $775.71 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $445.64 | 2019-2021 | |
| Novo Nordisk INC | $421.13 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $367.46 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $252.70 | 2019-2025 | |
| Lilly USA, LLC | $227.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $172.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $134.10 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $127.00 | 2019-2025 | Repatha, Repatha, Otezla |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Merck Sharp & Dohme LLC | $98.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.33 | 2019-2024 | Xifaxan |
| Abbvie INC. | $77.81 | 2019-2024 | |
| Abbott Laboratories | $64.39 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.50 | 2019-2020 | |
| Dexcom, INC. | $50.58 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $40.94 | 2021-2022 | |
| Horizon Therapeutics Plc | $39.56 | 2022 | |
| Eisai INC. | $38.95 | 2021-2022 | |
| Ibsa Pharma INC. | $33.65 | 2020-2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $29.75 | 2024 | Givlaari |
| Boston Scientific Corporation | $28.60 | 2025 | Watchman Flx |
| Indivior INC. | $26.08 | 2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.24 | 2025 | Caplyta |
| Cardiovascular Systems INC. | $22.45 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.91 | 2025 | Recorlev |
| Gilead Sciences, INC. | $19.81 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.62 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $19.03 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2019 | |
| Allergan, INC. | $17.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.99 | 2022 | |
| Cequr Corporation | $15.73 | 2025 | Cequr Simplicity |
| Aytu Biopharma, INC. | $14.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.